MedTrace Logo

A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z

NCT06929260 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2026-01-22

No results posted yet for this study

Summary

The study aims to assess the effect of ceralasertib on the pharmacokinetics (PK) of Drug X, Drug Y and Drug Z in participants with advanced solid tumours.

Conditions

  • Advanced Solid Tumours

Interventions

DRUG

Ceralasertib

Participants will receive repeated dosing of ceralasertib from Day 1 to Day 7 until steady state.

DRUG

Drug X

Participants will receive a single dose of Drug X on Day 5 and Day 22.

DRUG

Drug Y

Participants will receive a single dose of Drug Y on Day 7 and Day 28.

DRUG

Drug Z

Participants will receive a single dose of Drug Z on Day 7 and Day 28.

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-21
Primary Completion
2025-10-15
Completion
2025-12-18

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06929260 on ClinicalTrials.gov